BALTIMORE, May 08, 2025--TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) ("TNF" or the "Company"), a clinical stage biopharmaceutical company committed to developing novel therapies for autoimmune and ...

In a challenging market environment, TNFA stock has reached a new 52-week low, with shares plummeting to $0.48. According to InvestingPro data, the stock's RSI indicates oversold conditions ...

TNF Pharmaceuticals has a beta of 2.13, indicating that its stock price is 113% more volatile than the S&P 500. Comparatively, TNF Pharmaceuticals’ peers have a beta of 1.29, indicating that ...

Shares of TNF Pharmaceuticals, Inc. (TNFA) traded nearly 5% higher on Tuesday afternoon after it announced a partnership with Renova Health for the application of AI and machine learning ...

Nasdaq provides an interactive stock information chart to view history. Downloadable stock history data table is also accessible by clicking on Data Table on the navigation tool bar. If you have ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

9.6% of TNF Pharmaceuticals shares are owned by institutional investors. Comparatively, 44.7% of shares of all “Diagnostic substances” companies are owned by institutional investors. 1.2% of ...

Reveal insider sentiment with alternative data that tracks buy and sell trades made by top managers and company directors.

Short interest is currently not available. Nasdaq provides information of company’s short interest and the average days it takes to cover them. Short interest and days to cover can be used to ...

BALTIMORE, April 22, 2025--TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) ("TNF" or the "Company"), a clinical stage biopharmaceutical company committed to developing novel therapies for autoimmune and ...